The Particle Therapy Co-Operative Group (PTCOG) was founded in 1985 and is a non-profit worldwide organization of scientists and professionals interested in proton, light ion and heavy charged particle radiotherapy. The mission of PTCOG is to promote science, technology and practical clinical application of particle therapy. PTCOG promotes education and global activities in the field of particle radiation therapy, organizing scientific meetings and educational sessions. In 2019, in Manchester UK, BNCT was included in the PTCOG international conference programme with parallel oral and poster sessions. In this meeting, the PTCOG BNCT working group was created and the first meeting was held with several members for ISNCT that were present. In 2020 the second PTCOG BNCT working group meeting (on September 11th) was held virtually, in which the President and more ISNCT members participated. This PTCOG BNCT working group is open to anyone who would like to participate.
The PTCOG 59 meeting was virtually organized due to COVID pandemia. It was held on September 13th and 14th, 2020. The congress consisted on Educational sessions, Plenary sessions (keynote sessions), Sponsor pitches and sessions. In this virtual congress, BNCT was also present with 10 presentations (between oral and poster presentations).
BNCT oral presentations
DEVELOPMENT OF REAL-TIME NEUTRON DETECTORS AT WHOLE BODY POSITION IN BNCT. Speaker: N. Matsubayashi, JAPAN
TISSUE IMPRINTS IN NUCLEAR TRACK DETECTORS TO ENHANCE SPATIAL RESOLUTION OF NEUTRON AUTORADIOGRAPHY. Speaker: A. Portu, ARGENTINA
SKIN AND MUCOSAL REACTION OF REACTOR BASED BNCT. Speaker: K. Nakai, JAPAN
BNCT posters presentations
A CYCLOTRON-BASED BNCT SYSTEM AND THE CURRENT STATUS OF ITS REGULATORY PROCESS FOR THE MEDICAL DEVICE IN JAPAN. Shin Masui and Tomoyuki Asano. JAPAN
ALBUMIN-BASED BORON DELIVERY TO TUMOR BY ACTIVE TARGETING VIA αvβ3 INTEGRIN. Hiroyuki Nakamura, Kazuki Kawai, Kai Nishimura, Satoshi Okada, Shinichi Sato, Takushi Takata, Minoru Suzuki. JAPAN
BNCT (BORON NEUTRON CAPTURE THERAPY) MEDIATED BY BPA+GLUTAMINE IN THE HAMSTER CHEEK POUCH ORAL CANCER MODEL. A. Monti Hughes, I.S. Santa Cruz, L.N. De Leo, P.S. Ramos, J.A. Goldfinger, S. Thorp, P. Curotto, E.C.C. Pozzi, M.C. Hsiao, M.A. Palmieri, M.A. Garabalino, V.A. Trivillin, A.E. Schwint. ARGENTINA
BORON COMPOUNDS – PHARMACEUTICAL PRECURSORS IN BNCT METHOD. Karolina Wójciuk, Anna Bojanowska-Czajka, Ewelina Chajduk, Michał Dorosz, Grzegorz Wójciuk, Janusz Kocik. POLAND
EVALUATION SYSTEM FOR RECURRENT HEAD AND NECK CANCER. Kazuyo Igawa, Ryo Ogawara, Tamon Kusumoto, Mitsuru Suda, Tsuyoshi Hamano, Minoru Suzuki, Yasuaki Ichikawa, Akira Sasaki. JAPAN
IN VIVO EVALUATION OF A PHENYLBORONIC ACID-INSTALLED, ACTIVELY TARGETED NOVEL BNCT AGENT AGAINST MELANOMA-BEARING MOUSE MODEL. Yoshitaka MATSUMOTO, Ahram KIM, Nobuyoshi FUKUMITSU, Minoru SUZUKI, Yukio NAGASAKI and Hideyuki SAKURAI. JAPAN
PERFORMANCE TEST OF THE NEW BOLUS IN BNCT USING CYCLOTRON-BASED EPITHERMAL NEUTRON SOURCE AND 3D PRINTED WATER PHANTOM. Akinori Sasaki, Takushi Takata, Yoshihiro Kudo, Minoru Suzuki, Yoshinori Sakurai, Toshinori Mitsumoto, Hiroki Tanaka. JAPAN